Devasthale P, Wang Y, Wang W, Fevig J, Feng J, Wang A, Harrity T, Egan D, Morgan N, Cap M, Fura A, Klei HE, Kish K, Weigelt C, Sun L, Levesque P, Moulin F, Li YX, Zahler R, Kirby MS, Hamann LG (2013) <br />Optimization of Activity, Selectivity, and Liability Profiles in 5-Oxopyrrolopyridine DPP4 Inhibitors Leading to Clinical Candidate (Sa)-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]py ridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778)<br /><i>Journal of Medicinal Chemistry</i> <b>56</b>: 7343<br /><br />Harstad EB, Rosenblum JS, Gorrell MD, Achanzar WE, Minimo L, Wu J, Rosini-Marthaler L, Gullo R, Ordway ND, Kirby MS, Chadwick KD, Cosma GN, Moyer CF (2013) <br />DPP8 and DPP9 expression in cynomolgus monkey and Sprague Dawley rat tissues<br /><i>Regul Pept</i> <b>186C</b>: 26<br /><br />Zhao G, Kwon C, Wang A, Robertson JG, Marcinkeviciene J, Parker RA, Kirby MS, Hamann LG (2013) <br />Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors<br /><i>Bioorganic & Medicinal Chemistry Lett</i> <b>23</b>: 1622<br /><br />Wang A, Dorso C, Kopcho L, Locke G, Langish R, Harstad E, Shipkova P, Marcinkeviciene J, Hamann L, Kirby MS (2012) <br />Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor<br /><i>BMC Pharmacol</i> <b>12</b>: 2<br /><br />Wang W, Devasthale P, Wang A, Harrity T, Egan D, Morgan N, Cap M, Fura A, Klei HE, Kish K, Weigelt C, Sun L, Levesque P, Li YX, Zahler R, Kirby MS, Hamann LG (2011) <br />7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site<br /><i>Bioorganic & Medicinal Chemistry Lett</i> <b>21</b>: 6646<br /><br />Brigance RP, Meng W, Fura A, Harrity T, Wang A, Zahler R, Kirby MS, Hamann LG (2010) <br />Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes<br /><i>Bioorganic & Medicinal Chemistry Lett</i> <b>20</b>: 4395<br /><br />Meng W, Brigance RP, Chao HJ, Fura A, Harrity T, Marcinkeviciene J, O'Connor SP, Tamura JK, Xie D, Zhang Y, Klei HE, Kish K, Weigelt CA, Turdi H, Wang A, Zahler R, Kirby MS, Hamann LG (2010) <br />Discovery of 6-(Aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxa mides as Potent, Selective Dipeptidyl Peptidase-4 (DPP4) Inhibitors<br /><i>Journal of Medicinal Chemistry</i> <b>53</b>: 5620<br /><br />O'Connor SP, Wang Y, Simpkins LM, Brigance RP, Meng W, Wang A, Kirby MS, Weigelt CA, Hamann LG (2010) <br />Synthesis, SAR, and atropisomerism of imidazolopyrimidine DPP4 inhibitors<br /><i>Bioorganic & Medicinal Chemistry Lett</i> <b>20</b>: 6273<br /><br />Metzler WJ, Yanchunas J, Weigelt C, Kish K, Klei HE, Xie D, Zhang Y, Corbett M, Tamura JK, He B, Hamann LG, Kirby MS, Marcinkeviciene J (2008) <br />Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation<br /><i>Protein Science</i> <b>17</b>: 240<br /><br />Simpkins LM, Bolton S, Pi Z, Sutton JC, Kwon C, Zhao G, Magnin DR, Augeri DJ, Gungor T, Rotella DP, Sun Z, Liu Y, Slusarchyk WS, Marcinkeviciene J, Robertson JG, Wang A, Robl JA, Atwal KS, Zahler RL, Parker RA, Kirby MS, Hamann LG (2007) <br />Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors<br /><i>Bioorganic & Medicinal Chemistry Lett</i> <b>17</b>: 6476<br /><br />Magnin DR, Taunk PC, Robertson JG, Wang A, Marcinkeviciene J, Kirby MS, Hamann LG (2006) <br />Seco-prolinenitrile inhibitors of dipeptidyl peptidase IV define minimal pharmacophore requirements at P1<br /><i>Bioorganic & Medicinal Chemistry Lett</i> <b>16</b>: 1731<br /><br />Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG (2005) <br />Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes<br /><i>Journal of Medicinal Chemistry</i> <b>48</b>: 5025<br /><br />Kopcho LM, Kim YB, Wang A, Liu MA, Kirby MS, Marcinkeviciene J (2005) <br />Probing prime substrate binding sites of human dipeptidyl peptidase-IV using competitive substrate approach<br /><i>Archives of Biochemistry & Biophysics</i> <b>436</b>: 367<br /><br />Zhao G, Taunk PC, Magnin DR, Simpkins LM, Robl JA, Wang A, Robertson JG, Marcinkeviciene J, Sitkoff DF, Parker RA, Kirby MS, Hamann LG (2005) <br />Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors<br /><i>Bioorganic & Medicinal Chemistry Lett</i> <b>15</b>: 3992<br /><br />